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polymorphic VT, while A and L were equally effective in hemodynamically unstable sus-
tained monomorphic VT. Patients with polymorphic VT and a wide QRS were more likely
to convert with A while L was ineffective in these patients.
1154-98 Ventricular Fibrillation Triggered by Thoracic 
Compression During Out-of-Hospital Cardiac Arrest 
Resuscitation in the Piacenza Vita Project
Alessandro Capucci, Daniela Aschieri, Simona Bennati, Massimo Piepoli, Giovanni 
Quinto Villani, Giovanni Quinto Villani, Maurizio Arvedi, Gust Bardy, G.da Saliceto 
Hospital, Piacenza, Italy
Background. Decreasing the delay to defibrillation by introducing the automated external
defibrillators (AEDs) has increased the number of potential first responders. The role of
CPR training in lay first responders is still debated and data on the benefit of sterno-tho-
racic compression when a spontaneous cardiac rhythm (SCR) has been recovered are
scanty. We examined whether: 1) CPR may influence survival ; 2) sterno-thoracic com-
pression after recovery of SCR has benefic effects.
Methods. Piacenza Progetto Vita (PPV) involves 2631 lay volunteers trained by a 4 hour
course to intervene only with the AED in cases of suspected sudden cardiac arrest
(SCA). 135 consecutive cases of SCA with ventricular fibrillation (VF) were treated. Sur-
vival rate was evaluated. and EKG tracing was analyzed where early defibrillation per-
formed by lay volunteers was followed by traditional CPR by EMS.
Results. 77/135 cases were treated by PPV volunteers and 58/135 by EMS. Survival rate
from shockable rhythm was 32% (25/77) in PPV group vs 18% (11/58) in EMS group (p <
0.05). The EKG analysis of 25 survivors of group PPV showed: 1) 19 pts had more than
1 episode of VF (1.9 VF/pt) for a total of 36 episodes; 2) the time from effective shock and
the first spontaneous QRS was 16.2+17.1 sec (median 3-48 sec); 3) the mean rate of
first SCR was 34 + 12 bpm; 4) sinus rhythm was present as first SCR after 12 (31%) ven-
tricular fibrillation; 4) sinus rhythm compared earlier than wide QRS (4+2 sec vs 28+12
sec, p < 0.001); 5) chest compression was performed in 22 cases irrespective of the
presence of SCR. In 14 cases sterno-thoracic compression was directly associated with
VF induction;
Conclusion. Defibrillation alone increase survival in out of hospital cardiac . Post defibril-
lation sterno-thoracic compression may trigger ventricular fibrillation. Sterno thoracic
compression may be delayed of almost 30-60 seconds when spontaneous rhythm has
been recovered.
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861-1 Direct, Selective, Factor Xa Inhibition in Patients With 
Non-ST Elevation Acute Coronary Syndromes From the 
United States, Canada, and Japan: Results of the 
XaNADU-ACS Trial
John H. Alexander, Hongqiu Yang, Richard C. Becker, Kazuhisa Kodama, Christopher K. 
Dyke, Shaun G. Goodman, Neal S. Kleiman, Judith S. Hochman, Peter B. Berger, Eric A. 
Cohen, Michael Lincoff, Edwin G. Bovill, Chuichi Kawai, Paul W. Armstrong, Robert A. 
Harrington, Duke University Medical Center, Durham, NC
Background: New anticoagulants are needed for patients with non-ST elevation acute
coronary syndromes (ACS). We investigated the efficacy and safety of a novel direct,
selective, factor Xa inhibitor, DX-9065a (Daiichi Pharma. LTD, Inc.) compared to unfrac-
tionated heparin (UFH).
Methods: Patients with ACS from the US (n=313), Canada (n=45), and Japan (n=47)
were randomized 1:1:1 to one of two blinded regimens of DX-9065a and UFH placebo or
to weight adjusted UFH and DX-9065a placebo. DX-9065a was administered as a bolus,
3 hour rapid infusion, and maintenance infusion of 0.025 mg/kg, 0.04 mg/kg/hr; and
0.012 mg/kg/hr in one regimen and 0.05 mg/kg, 0.08 mg/kg/hr, and 0.024 mg/kg/hr in the
other. The primary endpoint was death, MI, urgent revascularization, or recurrent
ischemia on continuous ST-segment monitoring. Projected death, MI, urgent revascular-
ization and recurrent ischemia rates were 3.0%, 9.0%, 4.5%, 30.0% for UFH.
Results: Enrollment was completed on September 8, 2003. Preliminary results are avail-
able on 339 patients. The trial remains blinded so aggregate baseline, in-hospital man-
agement, and outcome data by country are presented. *includes CABG.
Conclusions: Direct selective, factor Xa inhibition may be an attractive alternative anti-
coagulant in patients with ACS. This is the first randomized experience with DX-9065a in
ACS and will provide the basis for further phase 3 investigation. Complete efficacy and
safety data from XaNADU ACS will be available at the ACC.
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861-2 Enoxaparin Versus Unfractionated Heparin in Patients 
Treated With Tirofiban, Aspirin, and an Early 
Conservation Initial Management Strategy: Results 
From the A Phase of the A to Z Trial
James A. de Lemos, Michael A. Blazing, Harvey D. White, Keith A. Fox, Peter M. 
DiBattiste, Joanne Palmisano, David W. Bilheimer, William E. Brady, Laura H. Gardner, 
Karen E. Ramsey, Eldrin F. Lewis, Marc A. Pfeffer, Robert M. Califf, Eugene Braunwald, 
University of Texas Southwestern Medical Center, Dallas, TX, Duke University Medical 
Center, Durham, NC
Introduction: In high-risk patients with non-ST elevation acute coronary syndromes
(ACS), enoxaparin (enox) is generally preferred to unfractionated heparin (UFH). How-
ever, few data are available comparing enox with UFH in patients receiving concomitant
glycoprotein IIb/IIIa inhibitors.
Methods: The A phase of the A to Z trial randomized 3987 patients with non ST eleva-
tion ACS to receive either enox (n= 2026) or UFH (n= 1961) in combination with aspirin
and tirofiban. Inclusion required either ST depression or cardiac biomarker elevation.
While the selection of an early management strategy (invasive or conservative) was at
the discretion of the local investigator, investigators were asked to designate their intent
for an invasive or conservative strategy at the time of randomization. Comparison of enox
with UFH in the subgroup of patients for whom an invasive strategy was planned is lim-
ited by the protocol design: crossover from enox to UFH was permitted at the time of
catheterization. In contrast, in subjects for whom an early conservative strategy was
planned, crossover was rare (4.4%), allowing a more direct comparison of the two anti-
thrombotic strategies. The primary endpoint was a composite of all-cause mortality, new
MI, and documented refractory ischemia within 7 days of randomization. Independent
subjective and objective assessments of bleeding using TIMI definitions were collected.
Results: A conservative strategy was planned in 872 patients (44.6%) randomized to
UFH and 906 patients (44.8%) randomized to enox. Among patients with a planned con-
servative strategy, the primary endpoint occurred in 10.6% of patients randomized to
UFH and 7.7% of patients randomized to enox (HR 0.73; 95% CI 0.53-0.99). In this sub-
group, the combined rate of TIMI major, minor, or loss no-site bleeding was 1.3% in
patients treated with UFH and 1.8% in those treated with enox (p=0.44).
Conclusions: When a conservative approach to catheterization and PCI was planned
for patients receiving tirofiban and aspirin, enoxaparin was associated with superior effi-
cacy and similar bleeding vs UFH.
Preliminary Results
United States
n=248
Canada
n=45
Japan
n=47
Overall
n=399
Age (yrs) 56 (49,66) 64 (56,71) 68 (60,72) 59 (51,69)
Female (%) 30 23 38 30
Weight (kg) 87 (75,100) 83 (70,94) 60 (56,69) 82 (69,96)
Diabetes (%) 25 16 21 24
Hypertension (%) 53 59 53 54
Prior CHF (%) 7 7 4 6
Prior MI (%) 28 32 11 26
Aspirin (%) 92 82 96 91
B-Blocker (%) 83 90 32 76
ACE-I (%) 61 79 21 57
Lipid Rx (%) 80 79 30 72
GP IIb/IIIa (%) 71 47 0 57
Cath (%) 98 93 100 98
PCI (%) 54 43 62 54
CABG (%) 19 27 2 18
Death (%) 2 2 0 2
MI (%) 9 9 13 9
Urgent Revasc (%) 4 14 13 6
ST-monitor ischemia (%) 24 25 24 24
Composite (%) 25 32 36 28
TIMI Major Bleeding (%)* 14 25 2 14
TIMI Minor Bleeding (%) 7 5 7 6
Any Bleeding (%)* 33 57 30 36
Transfusion (%)* 12 21 4 12
